Based on recent reports suggesting synergy between epigenome-targeting agents and PARP inhibitors,25 with HDAC inhibitors inducing a BRCA-ness state,17,26 we tested differential growth responses of isogenic cancer cells carrying or not a BRCA1 mutation to epigenome-modifying agents. This evidence concerns the gene HDAC9 and cancer.